Vertex Pharmaceuticals Incorporated (VRTX)
Last Price$484.20.8%
Market Cap$124.7B
WACC
7.5%
Cost of Equity
7.6%
Cost of Debt
0.1%
Debt to Equity
1.4%
Beta
1.0
Stock quality
6/10
Good
VRTX WACC
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
VRTX Cost of Equity
Crunching data... Almost there!
VRTX vs Peer Set: Discount Rate Comparison
WACC
Cost of Equity
General
Discount rate
financials
Company name
Revenue growth
EPS growth
Net Income margin
Vertex Pharmaceuticals IncorporatedVRTX
7.5%
10.5%
8.3%
36.7%
Median Peer Set
7.5%
14.5%
21.0%
20.3%
Incyte CorporationINCY
7.7%
8.9%
74.5%
16.2%
Royalty Pharma plcRPRX
7.6%
5.2%
3,386.7%
48.2%
Summit Therapeutics Inc.SMMT
7.6%
(100.0%)
160.5%
N/A
BioNTech SEBNTX
7.6%
(77.4%)
(89.7%)
24.4%
United Therapeutics CorporationUTHR
7.5%
20.2%
31.7%
42.3%
Regeneron Pharmaceuticals, Inc.REGN
7.4%
8.3%
10.4%
31.1%
Alnylam Pharmaceuticals, Inc.ALNY
7.4%
76.2%
(62.2%)
(24.1%)
Novo Nordisk A/SNVO
7.4%
24.9%
142.8%
34.8%
BeiGene, Ltd.BGNE
4.9%
73.7%
(56.5%)
(35.9%)
argenx SEARGX
negative
198.6%
(60.5%)
(24.1%)
Explore more intrinsic value tools hub for VRTX
Peter Lynch Fair Value
Margin of safety
Reverse DCF
Relative Value
DCF value calculator
Ben Graham Fair Value
Intrinsic Value
Peter Lynch charts
Earnings growth model
Earnings Power Value
FAQ
What is Vertex Pharmaceuticals Incorporated's discount rate as of Feb 21, 2025?
As of Feb 21, 2025, Vertex Pharmaceuticals Incorporated's discount rate is 7.54%. This rate is determined based on the weighted average cost of capital (WACC) and the cost of equity, factoring in Vertex Pharmaceuticals Incorporated's capital structure and risk profile.
What is Vertex Pharmaceuticals Incorporated's weighted average cost of capital (WACC)?
Vertex Pharmaceuticals Incorporated's WACC as of Feb 21, 2025, is 7.54%. This value is calculated by blending the cost of debt and cost of equity, reflecting the company’s overall cost of financing its operations.
What is Vertex Pharmaceuticals Incorporated's cost of equity?
Vertex Pharmaceuticals Incorporated's cost of equity is 7.6%, as of Feb 21, 2025. This is the return that shareholders expect based on the stock's risk level and market conditions, used to calculate the discount rate for valuing future cash flows.